Genexine Stock Current Liabilities

Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

In accordance with the recently published financial statements, Genexine has a Current Liabilities of 5.16 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current liabilities for all Republic of Korea stocks is notably lower than that of the firm.

The Macroaxis Fundamental Analysis modules help investors analyze Genexine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genexine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genexine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Genexine financial ratios help investors to determine whether Genexine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genexine with respect to the benefits of owning Genexine security.